http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd6d222dd0899808696d3da5c06eb672
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Irimura |
| name | Tatsuro Irimura |
| given-name | Tatsuro |
| organization-name | Laboratory of Cancer Biology and Molecular Immunology Graduate School of Pharmaceutical Sciences University of Tokyo Bunkyo‐ku Tokyo Japan Division of Chemical Toxicology and Immunochemistry, Faculty of Pharmaceutical Sciences, University of Tokyo , Tokyo , Japan Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo. Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan Subcommittee on Non‐clinical Studies The Science Board to the Pharmaceuticals and Medical Devices Agency Tokyo Japan; Juntendo University School of Medicine Tokyo Japan Laboratory of Cancer Biology, University of Tokyo, Tokyo 113-8657, Japan *Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; and Division of Glycobiologics, Intractable Disease Research Center, Juntendo University School of Medicine, Tokyo, Japan. Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. Graduate School of Pharmaceutical Sciences University of Tokyo Tokyo Japan 2Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan Laboratory of Cancer Biology and Molecular Immunology Graduate School of Pharmaceutical Sciences University of Tokyo Tokyo Japan Institute for Medical Innovation, St. Luke's International Medical Center, Tokyo, Japan Division of Glycobiologics, Intractable Disease Research Center, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo, Japan 6Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113-0033, Japan Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan Department of Tumor Biology, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston 77030 Juntendo University School of Medicine Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan, Department of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan, and Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, 117997 Moscow, Russia Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo , Tokyo, Japan Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421 Japan Institute of medical innovation, St. Luke's international Hospital, Chuo-ku, Tokyo, Japan Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan Graduate School of Pharmaceutical Science, University of Tokyo, Tokyo, Japan Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo , Japan Laboratory of Cancer Biology and Molecular Immunology Graduate School of Pharmaceutical Sciences The University of Tokyo Tokyo Japan; Institute for Medical Innovation St. Luke's International University Tokyo Japan Authors' Affiliations: 1Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, the University of Tokyo; 2Center for Medical System Innovation, the University of Tokyo Global COE Program, Tokyo, Japan; and 3Department of Immunology, Institute for Biological Research “Sinisa Stankovic,” Belgrade University, Belgrade, Serbia Laboratory of Cancer Biology and Molecular Immunology Graduate School of Pharmaceutical Sciences The University of Tokyo Tokyo Japan Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113-0033, Japan 1Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo; From the Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan; the Department of Microbiology, University of Shizuoka, School of Pharmaceutical Sciences, Shizuoka, Japan; and the Molecular Biology Section, Division of Biological Sciences, University of California, San Diego, La Jolla, CA. Division of Glycobiologics Intractable Disease Research Center Juntendo University Japan Department of Cancer Biology and Molecular Immunochemistry, Faculty of Pharmaceutical Sciences, The University of Tokyo , Tokyo , Japan |
Incoming Links
Showing number of triples: 1 to 252 of 252.